MGCD0103, a selective histone deacetylase inhibitor, coameliorates oligomeric Aβ(25‐35)‐induced anxiety and cognitive deficits in a mouse model

AIMS: Recently, histone deacetylase (HDAC) inhibitors are considered a possible therapeutic strategy in Alzheimer's disease (AD). However, HDACi treatments exhibit diverse functions with unfavorable effects in AD. Thus, the development of selective HDACi without side effects is urgently needed....

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Hei‐Jen, Huang, Hsin‐Yu, Hsieh‐Li, Hsiu Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488906/
https://www.ncbi.nlm.nih.gov/pubmed/29978554
http://dx.doi.org/10.1111/cns.13029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488906/
https://www.ncbi.nlm.nih.gov/pubmed/29978554
http://dx.doi.org/10.1111/cns.13029

Ejemplares similares